MA39740A - Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes - Google Patents

Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes

Info

Publication number
MA39740A
MA39740A MA039740A MA39740A MA39740A MA 39740 A MA39740 A MA 39740A MA 039740 A MA039740 A MA 039740A MA 39740 A MA39740 A MA 39740A MA 39740 A MA39740 A MA 39740A
Authority
MA
Morocco
Prior art keywords
compositions
methods
estrogen receptor
receptor mutants
modulating estrogen
Prior art date
Application number
MA039740A
Other languages
English (en)
Inventor
Maneval Edna Chow
Lori Friedman
Jeffrey H Hager
James D Joseph
Jing Qian
Debasish F Roychowdhury
Deepak Sampath
Nicholas D Smith
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of MA39740A publication Critical patent/MA39740A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes et des compositions pour le traitement d'une pathologie liée à er caractérisée par une mutation dans le gène
MA039740A 2014-03-13 2015-03-12 Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes MA39740A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461952728P 2014-03-13 2014-03-13
US201461981708P 2014-04-18 2014-04-18

Publications (1)

Publication Number Publication Date
MA39740A true MA39740A (fr) 2017-01-18

Family

ID=52682706

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039740A MA39740A (fr) 2014-03-13 2015-03-12 Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes

Country Status (14)

Country Link
US (1) US9855270B2 (fr)
EP (1) EP3116496A1 (fr)
JP (1) JP2017509631A (fr)
KR (1) KR20160132029A (fr)
CN (1) CN106488767A (fr)
AU (1) AU2015228860A1 (fr)
BR (1) BR112016020953A2 (fr)
CA (1) CA2941161A1 (fr)
IL (1) IL247250A0 (fr)
MA (1) MA39740A (fr)
MX (1) MX2016011698A (fr)
RU (1) RU2016137150A (fr)
SG (1) SG11201607339VA (fr)
WO (1) WO2015136017A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956276B2 (en) 2012-01-19 2018-05-01 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
EP2970130A4 (fr) 2013-03-14 2016-08-03 Seragon Pharmaceuticals Inc Modulateurs des récepteurs des strogènes polycycliques et leurs utilisations
WO2014205138A1 (fr) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Modulateur des récepteurs d'œstrogènes et ses utilisations
MX2015016171A (es) 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
AU2014334531B2 (en) * 2013-10-18 2019-05-16 The Regents Of The University Of Michigan Systems and methods for determining a treatment course of action
WO2016007499A1 (fr) 2014-07-07 2016-01-14 Duke University Vaccins contre un isoforme oncogène d'her2 (erbb2) et leurs méthodes d'utilisation
US20170196952A1 (en) 2014-07-07 2017-07-13 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
CN106660969A (zh) 2014-08-11 2017-05-10 豪夫迈·罗氏有限公司 雌激素受体调节剂的结晶形式
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
EP3274476B1 (fr) 2015-03-25 2023-06-07 The General Hospital Corporation Analyse numérique de cellules tumorales circulantes dans des échantillons de sang
EP3303326B1 (fr) 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Modulateurs des récepteurs d'oestrogènes hétérocycliques et leurs utilisations
WO2017060326A1 (fr) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Procédé pour la préparation d'acide (e)-3-(4-((e)-2-(2-chloro-4-fluorophényl)-1-(1h-indazol-5-yl)but-1-én-1-yl)phényl)acrylique
ES2935125T3 (es) 2015-12-09 2023-03-01 Univ Illinois Reguladores a la baja selectivos de los receptores de estrógenos con base en benzotiofeno
CN108697779B (zh) 2016-01-07 2023-09-19 杜克大学 癌症疫苗和递送方法
KR102479822B1 (ko) 2016-02-05 2022-12-21 인벤티스바이오 엘엘씨 선택적 에스트로겐 수용체 분해제 및 이들의 용도
MA45280B1 (fr) 2016-03-02 2021-08-31 Eisai R&D Man Co Ltd Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
AU2017239348B2 (en) * 2016-03-25 2020-03-12 Luoxin Healthcare Science and Technology Development (Beijing) Ltd. Substituted-indole compounds as estrogen receptor down-regulators
CA3022377A1 (fr) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Mesure ciblee de l'activite transcriptionnelle liee aux recepteurs hormonaux
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
FI3478286T3 (fi) 2016-06-29 2024-03-14 Tesaro Inc Menetelmiä munasarjasyövän hoitamiseksi
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
JP7007364B2 (ja) * 2016-08-18 2022-02-10 エフ．ホフマン－ラ ロシュ アーゲー エストロゲン受容体ｅｓｒ１変異の検出用のマルチプレックス対立遺伝子特異的ｐｃｒアッセイ
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
NZ752443A (en) 2016-10-11 2022-11-25 Univ Duke Lasofoxifene treatment of er+ breast cancer
WO2018081168A2 (fr) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène
US11371101B2 (en) 2016-10-27 2022-06-28 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
AR110728A1 (es) 2017-01-06 2019-04-24 G1 Therapeutics Inc Terapia combinada para el tratamiento del cáncer
TW201835064A (zh) 2017-02-10 2018-10-01 美商G1治療公司 苯并噻吩雌激素受體調節劑
JP2020529403A (ja) * 2017-07-28 2020-10-08 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー アクリル酸類似体
WO2019057201A1 (fr) * 2017-09-25 2019-03-28 罗欣生物科技（上海）有限公司 Forme cristalline d'un inhibiteur du récepteur des œstrogènes et son procédé de préparation
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
CA3087060A1 (fr) * 2017-12-27 2019-07-04 Tesaro, Inc. Methodes de traitement du cancer
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
TWI915239B (zh) 2018-06-21 2026-02-11 瑞士商赫孚孟拉羅股份公司 3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程，包括其使用方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111184863B (zh) * 2018-11-15 2023-06-16 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途
KR102858291B1 (ko) 2018-11-28 2025-09-12 뤄신 파마슈티컬 (상하이) 컴퍼니 리미티드 에스트로겐 수용체 하향 조절제의 염 형태와 결정형, 및 이의 제조방법
WO2020128972A1 (fr) 2018-12-20 2020-06-25 Novartis Ag Schéma posologique et combinaison pharmaceutique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione
CN113164467B (zh) * 2018-12-24 2023-12-26 益方生物科技(上海)股份有限公司 选择性雌激素受体降解剂的新型盐
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021015672A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
CA3138058A1 (fr) 2019-05-20 2020-11-26 Matthew T. Burger Conjugues anticorps-medicament inhibiteurs de mcl-1 et procedes d'utilisation
JP2022537330A (ja) * 2019-06-19 2022-08-25 江蘇恒瑞医薬股▲ふん▼有限公司 インダゾール誘導体、その製造方法及び医薬上のその使用
CN110982807B (zh) * 2019-12-17 2022-04-29 云南农业大学 一种高效稳定的纤维素酶突变体
EP4069225A4 (fr) * 2019-12-20 2023-12-27 Recurium IP Holdings, LLC Combinaisons
MX2022007628A (es) * 2019-12-20 2022-08-25 Recurium Ip Holdings Llc Combinaciones.
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
MX2022010425A (es) * 2020-03-06 2022-09-07 Olema Pharmaceuticals Inc Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
AU2021269612A1 (en) 2020-05-15 2023-01-05 Jiangsu Simcere Pharmaceutical Co., Ltd. Pyrrolidine compound and use thereof
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CR20230283A (es) 2020-11-24 2023-07-27 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
WO2022115451A1 (fr) 2020-11-24 2022-06-02 Novartis Ag Conjugués anticorps-médicament inhibiteurs de mcl-1 et procédés d'utilisation
KR20230170644A (ko) 2021-02-02 2023-12-19 르 라보레또레 쎄르비에르 선택적 bcl-xl protac 화합물 및 사용 방법
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022245124A1 (fr) * 2021-05-18 2022-11-24 재단법인 대구경북첨단의료산업진흥재단 Nouveau composé d'éthène et composition pharmaceutique le comprenant en tant que principe actif pour la prévention ou le traitement du cancer
CN113293213A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测乳腺癌复发转移基因her2扩增的引物探针及其应用
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
EP4525926A1 (fr) 2022-05-20 2025-03-26 Novartis AG Conjugués anticorps-médicament inhibiteurs de met bcl-xl et leurs procédés d'utilisation
JP2025517430A (ja) 2022-05-20 2025-06-05 ノバルティス アーゲー Ｅｐｈａ２ ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用の方法
CA3262155A1 (fr) 2022-08-11 2024-02-15 Evexta Bio Composés pour le traitement du cancer
CN115820545A (zh) * 2022-12-28 2023-03-21 中国农业大学 提高卵母细胞体外成熟率的培养基及其应用
CN120752058A (zh) 2023-03-10 2025-10-03 诺华股份有限公司 panRAS抑制剂抗体-药物缀合物及其使用方法
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
WO2025168601A1 (fr) 2024-02-05 2025-08-14 Evexta Bio Composés d'azétidine de quinazoline carboxamide destinés à être utilisés dans le traitement de maladies hormono-dépendantes
TW202539634A (zh) 2024-04-10 2025-10-16 瑞士商諾華公司 Ｐａｎｒａｓ抑制劑及其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
ATE366745T1 (de) * 1999-12-07 2007-08-15 Sumitomo Chemical Co Mutant er-alpha und nachweissysteme für transaktivierung
HUE033581T2 (hu) * 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2013056178A2 (fr) * 2011-10-14 2013-04-18 Foundation Medicine, Inc. Nouvelles mutations de récepteur des estrogènes et leurs utilisations
SG11201403002RA (en) * 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
EP2791128A4 (fr) * 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc Nouveaux composés benzopyranes, compositions et utilisations de ceux-ci
MX2014011217A (es) * 2012-03-20 2015-03-10 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno y sus usos.
EP2970130A4 (fr) 2013-03-14 2016-08-03 Seragon Pharmaceuticals Inc Modulateurs des récepteurs des strogènes polycycliques et leurs utilisations
JP2016521557A (ja) * 2013-06-07 2016-07-25 キージーン・エン・フェー 標的配列決定のための方法
WO2014197826A1 (fr) * 2013-06-07 2014-12-11 Rana Therapeutics, Inc. Compositions et procédés permettant de moduler l'expression de foxp3
MX2015016171A (es) 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
WO2014205138A1 (fr) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Modulateur des récepteurs d'œstrogènes et ses utilisations
MX2016007282A (es) 2013-12-06 2016-09-07 Hoffmann La Roche Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
AU2015228859A1 (en) 2014-03-13 2016-07-07 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators

Also Published As

Publication number Publication date
WO2015136017A1 (fr) 2015-09-17
RU2016137150A3 (fr) 2018-10-19
AU2015228860A1 (en) 2016-09-08
SG11201607339VA (en) 2016-10-28
MX2016011698A (es) 2016-12-12
IL247250A0 (en) 2016-09-29
US9855270B2 (en) 2018-01-02
RU2016137150A (ru) 2018-04-18
US20150258099A1 (en) 2015-09-17
CN106488767A (zh) 2017-03-08
CA2941161A1 (fr) 2015-09-17
KR20160132029A (ko) 2016-11-16
BR112016020953A2 (pt) 2018-01-23
JP2017509631A (ja) 2017-04-06
EP3116496A1 (fr) 2017-01-18

Similar Documents

Publication Publication Date Title
IL247250A0 (en) Methods and compositions for modulating estrogen receptor mutants
PH12019500627A1 (en) Affinity-oligonucleotide conjugates and uses thereof
IL273058A (en) Compositions and methods for modulation of PKK expression
IL271659A (en) Compositions and methods for modulating expression of complement factor B
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
GB2556286A (en) Programmable voltage reference
MA39741A (fr) Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes
TW201613966A (en) SynTac polypeptides and uses thereof
MX2020000621A (es) Composiciones para usarse en inmunomodulacion.
IL247716A0 (en) Preparations and methods for the modulation of growth hormone receptor expression
SG10201900574SA (en) Virtual currency conversion device, method and computer program
EP3203275A4 (fr) Plaque de diffusion et son procédé de production
EP3189036A4 (fr) Compositions et méthodes pour traiter des troubles prolifératifs
EP3134120A4 (fr) Compositions et méthodes pour le traitement de troubles liés aux cytokines
EP3110446A4 (fr) Procédés et compositions pour le traitement de maladies associées à siglec-8
MX2017000374A (es) Metodos y composiciones que regulan el crecimiento del pelo.
EP3194027A4 (fr) Procédés et compositions pour le traitement de troubles psychotiques
EP3186269A4 (fr) Compositions, procédés et kits pour le traitement des troubles liés au complément
EP3220946A4 (fr) Compositions et procédés de traitement de l'intolérance au gluten et des troubles qui en découlent
MX2016009541A (es) Metodo para tratar vajilla.
UA106748U (uk) Пристрій для формування паливних матеріалів
MX2016012928A (es) Metodos y composiciones para inmunomodulacion.
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes